Ratings by Rodman & Renshaw (Elemer Piros)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/25/2025 | Cassava Sciences | SAVA | Maintain | Sell (N/A) |
|
Details | ||
| 3/19/2025 | BioXcel Therapeutics | BTAI | New Coverage | Buy (N/A) |
2.20 (1.48) |
-32.73% | Details | |
| 2/21/2025 | Telomir Pharma | TELO | New Coverage | Buy (N/A) |
4.21 (1.25) |
-70.31% | Details | |
| 2/7/2025 | GH Research PLC | GHRS | Maintain | Buy (N/A) |
|
Details | ||
| 2/3/2025 | GH Research PLC | GHRS | Maintain | Buy (N/A) |
|
Details | ||
| 1/28/2025 | INmune Bio Inc. | INMB | New Coverage | Buy (N/A) |
7.91 (1.33) |
-83.19% | Details | |
| 1/27/2025 | Compass Pathways | CMPS | Maintain | Buy (N/A) |
|
Details | ||
| 12/12/2024 | FibroBiologics | FBLG | New Coverage | Buy (N/A) |
2.40 (0.44) |
-81.67% | Details | |
| 12/6/2024 | Tharimmune, Inc. | THAR | New Coverage | Buy (N/A) |
2.03 (4.74) |
133.5% | Details | |
| 11/25/2024 | Cassava Sciences | SAVA | Downgrade | Sell (Buy) |
26.48 (2.03) |
-92.33% | Details | |
| 10/29/2024 | Quince Therapeutics Inc. | QNCX | New Coverage | Buy (N/A) |
0.99 (0.10) |
-89.9% | Details | |
| 10/23/2024 | Alto Neuroscience | ANRO | Downgrade | Neutral (Buy) |
14.53 (20.76) |
42.88% | Details | |
| 9/30/2024 | MIRA Pharmaceuticals Inc | MIRA | New Coverage | Buy (N/A) |
1.16 (1.16) |
0% | Details | |
| 9/4/2024 | Athira Pharma | ATHA | Downgrade | Neutral (Buy) |
2.83 (6.75) |
138.52% | Details | |
| 8/19/2024 | Athira Pharma | ATHA | New Coverage | Buy (N/A) |
2.93 (6.75) |
130.38% | Details | |
| 6/20/2024 | Alto Neuroscience | ANRO | New Coverage | Buy (N/A) |
11.15 (14.53) |
30.31% | Details | |
| 6/18/2024 | Forte Biosciences Inc. | FBRX | New Coverage | Buy (N/A) |
0.52 (28.76) |
5430.77% | Details | |
| 6/13/2024 | Cognition Therapeutics | CGTX | New Coverage | Buy (N/A) |
2.38 (1.03) |
-56.72% | Details | |
| 6/13/2024 | Cassava Sciences | SAVA | Maintain | Buy (N/A) |
|
Details | ||
| 6/13/2024 | Coya Therapeutics | COYA | New Coverage | Buy (N/A) |
8.00 (4.79) |
-40.13% | Details | |
| 6/4/2024 | Annovis Bio Inc. | ANVS | New Coverage | Buy (N/A) |
6.81 (2.49) |
-63.44% | Details |
